Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study

Carla Giordano, Manfredi Rizzo, Ivano Franzetti, Alessandra Dei Cas, Fabrizio Querci, Gian Pio Sorice, Vera Frison, Nino Cristiano Chilelli, Gaetano Leto, Giovanni Grossi, Federica D'Angelo, Manfredi Rizzo, Paola Berchialla, Edoardo Duratorre, Carmela Vinci, Carlo Mannina, Patrizia Li Volsi, Giuseppe Capobianco, Giuseppe Saglietti, Massimiliano PetrelliVeronica Sciannameo, Giuseppe Felace, Maurizio Poli, Achiropita Pucci, Salvatore Piro, Salvatore Arena, Silvestre Cervone, Roberta Chianetta, Paola D'Angelo, Daniele Bottigliengo, Paola Silvia Morpurgo, Carla Giordano, Olga Lamacchia, Massimo Boemi, Ioannis Karamouzis, Bruno Fattor, Raffaella Buzzetti, Paola Silvia Morpurgo, Gian Paolo Fadini, Natalino Simioni, Roberto Anichini, Paola Silvia Morpurgo, Francesco Andreozzi, Gianluca Aimaretti, Lucia Frittitta, Ivana Zavaroni, Giuseppe Penno, Emanuela Orsi, Franco Cavalot, Susanna Morano, Antonino Di Benedetto, Enzo Bonora, Massimo Boemi, Giorgio Sesti, Angelo Avogaro, Annunziata Lapolla, Raffaella Buzzetti, Anna Solini, Riccardo Bonadonna, Massimo Cigolini, Antonio Carlo Bossi, Adriano Gatti, Agostino Consoli, Manfredi Rizzo, Giuliana Cazzetta, Gloria Formoso, Eleonora Devangelio

Risultato della ricerca: Articlepeer review

9 Citazioni (Scopus)

Abstract

Aims: According to cardiovascular outcome trials, some sodium-glucose contransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) are recommended for secondary cardiovascular prevention in type 2 diabetes (T2D). In this real-world study, we compared the simultaneous reductions in HbA1c, body weight and systolic blood pressure after initiation of dapagliflozin or GLP-1RA as second or a more advanced line of therapy. Materials and methods: DARWIN-T2D was a retrospective multi-centre study conducted at diabetes specialist clinics in Italy that compared T2D patients who initiated dapagliflozin or GLP-1RA (exenatide once weekly or liraglutide). Data were collected at baseline and at the first follow-up visit after 3 to 12 months. The primary endpoint was the proportion of patients achieving a simultaneous reduction in HbA1c, body weight and systolic blood pressure. To reduce confounding, we used multivariable adjustment (MVA) or propensity score matching (PSM). Results: Totals of 473 patients initiating dapagliflozin and 336 patients initiating GLP-1RA were included. The two groups differed in age, diabetes duration, HbA1c, weight and concomitant medications. The median follow-up was 6 months in both groups. Using MVA or PSM, the primary endpoint was observed in 30% to 32% of patients, with no difference between groups. Simultaneous reduction of HbA1c, BP and SBP by specific threshold, as well as achievement of final goals, did not differ between groups. GLP-1RA reduced HbA1c by 0.3% more than the reduction achieved with dapagliflozin. Conclusion: In routine specialist care, initiation of dapagliflozin can be as effective as initiation of a GLP-1RA for attainment of combined risk factor goals.
Lingua originaleEnglish
pagine (da-a)1886-1894
Numero di pagine9
RivistaDiabetes, Obesity and Metabolism
Volume21
Stato di pubblicazionePublished - 2019

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Entra nei temi di ricerca di 'Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study'. Insieme formano una fingerprint unica.

Cita questo